FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013669698> ?p ?o ?g. }

• W2013669698 endingPage "2977" @default.
• W2013669698 startingPage "2972" @default.
• W2013669698 abstract "Women with HER-2 overexpressing metastatic breast carcinoma benefit from trastuzumab-based therapy, but trastuzumab does not cross the blood-brain barrier. The authors characterized central nervous system (CNS) disease in these women.Using pharmacy records, the authors retrospectively identified 153 women treated with trastuzumab alone or with chemotherapy for HER-2-positive metastatic breast carcinoma at Dana-Farber Partners Cancer Care from June 1998 to December 2000. A study cohort of 122 patients was identified after excluding patients without adequate clinical follow-up or who had CNS disease before trastuzumab treatment. Central nervous system disease was defined as one or more brain metastases or as leptomeningeal carcinomatosis. The median follow-up of this cohort was 23 months.Central nervous system metastases were identified in 34% of patients (95% confidence interval, 26-44%) at a median of 16 months after diagnosis of metastatic breast carcinoma and 6 months from the beginning of trastuzumab therapy. Ninety-three percent of patients with CNS disease presented with clinical symptoms. Five percent of patients with CNS disease had leptomeningeal involvement alone, although 14% had leptomeningeal involvement and parenchymal brain metastases. Fifty percent of patients were responding or had stable disease while receiving trastuzumab at other disease sites at the time of diagnosis of CNS metastasis. The median survival period after CNS metastases was 13 months. Fifty percent of patients died of progressive CNS disease. Patients receiving trastuzumab as first-line therapy for metastatic disease frequently developed brain metastases while responding to or stable on trastuzumab at other disease sites.Metastatic breast carcinoma to the CNS is common among patients receiving trastuzumab-based therapy, including patients responding to therapy outside the CNS. This may be due either to predilection for the CNS by HER-2-positive tumor cells and/or poor penetration of the CNS by trastuzumab or to improved visceral disease control leading to a longer life and onset of late tumor spread to the CNS. Efforts to characterize other risk factors for development of CNS disease, optimal screening algorithms, and new treatment strategies may be warranted." @default.
• W2013669698 created "2016-06-24" @default.
• W2013669698 creator A5019054377 @default.
• W2013669698 creator A5021514634 @default.
• W2013669698 creator A5028472820 @default.
• W2013669698 creator A5042936153 @default.
• W2013669698 creator A5055301443 @default.
• W2013669698 creator A5062329369 @default.
• W2013669698 creator A5063299870 @default.
• W2013669698 creator A5069347238 @default.
• W2013669698 creator A5070245248 @default.
• W2013669698 creator A5091620472 @default.
• W2013669698 date "2003-05-29" @default.
• W2013669698 modified "2023-09-29" @default.
• W2013669698 title "Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma" @default.
• W2013669698 cites W1836239578 @default.
• W2013669698 cites W1984093355 @default.
• W2013669698 cites W2007698881 @default.
• W2013669698 cites W2012594503 @default.
• W2013669698 cites W2042874073 @default.
• W2013669698 cites W2063613304 @default.
• W2013669698 cites W2088993386 @default.
• W2013669698 cites W2102506813 @default.
• W2013669698 cites W2129958415 @default.
• W2013669698 cites W2138692412 @default.
• W2013669698 cites W2141393790 @default.
• W2013669698 cites W2146406055 @default.
• W2013669698 cites W2154027407 @default.
• W2013669698 cites W2159459001 @default.
• W2013669698 cites W2222638000 @default.
• W2013669698 cites W2312647513 @default.
• W2013669698 cites W2318605753 @default.
• W2013669698 doi "https://doi.org/10.1002/cncr.11436" @default.
• W2013669698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12784331" @default.
• W2013669698 hasPublicationYear "2003" @default.
• W2013669698 type Work @default.
• W2013669698 sameAs 2013669698 @default.
• W2013669698 citedByCount "665" @default.
• W2013669698 countsByYear W20136696982012 @default.
• W2013669698 countsByYear W20136696982013 @default.
• W2013669698 countsByYear W20136696982014 @default.
• W2013669698 countsByYear W20136696982015 @default.
• W2013669698 countsByYear W20136696982016 @default.
• W2013669698 countsByYear W20136696982017 @default.
• W2013669698 countsByYear W20136696982018 @default.
• W2013669698 countsByYear W20136696982019 @default.
• W2013669698 countsByYear W20136696982020 @default.
• W2013669698 countsByYear W20136696982021 @default.
• W2013669698 countsByYear W20136696982022 @default.
• W2013669698 countsByYear W20136696982023 @default.
• W2013669698 crossrefType "journal-article" @default.
• W2013669698 hasAuthorship W2013669698A5019054377 @default.
• W2013669698 hasAuthorship W2013669698A5021514634 @default.
• W2013669698 hasAuthorship W2013669698A5028472820 @default.
• W2013669698 hasAuthorship W2013669698A5042936153 @default.
• W2013669698 hasAuthorship W2013669698A5055301443 @default.
• W2013669698 hasAuthorship W2013669698A5062329369 @default.
• W2013669698 hasAuthorship W2013669698A5063299870 @default.
• W2013669698 hasAuthorship W2013669698A5069347238 @default.
• W2013669698 hasAuthorship W2013669698A5070245248 @default.
• W2013669698 hasAuthorship W2013669698A5091620472 @default.
• W2013669698 hasConcept C121608353 @default.
• W2013669698 hasConcept C126322002 @default.
• W2013669698 hasConcept C143998085 @default.
• W2013669698 hasConcept C2775930923 @default.
• W2013669698 hasConcept C2776694085 @default.
• W2013669698 hasConcept C2778164965 @default.
• W2013669698 hasConcept C2779013556 @default.
• W2013669698 hasConcept C2779786085 @default.
• W2013669698 hasConcept C3018521938 @default.
• W2013669698 hasConcept C530470458 @default.
• W2013669698 hasConcept C71924100 @default.
• W2013669698 hasConceptScore W2013669698C121608353 @default.
• W2013669698 hasConceptScore W2013669698C126322002 @default.
• W2013669698 hasConceptScore W2013669698C143998085 @default.
• W2013669698 hasConceptScore W2013669698C2775930923 @default.
• W2013669698 hasConceptScore W2013669698C2776694085 @default.
• W2013669698 hasConceptScore W2013669698C2778164965 @default.
• W2013669698 hasConceptScore W2013669698C2779013556 @default.
• W2013669698 hasConceptScore W2013669698C2779786085 @default.
• W2013669698 hasConceptScore W2013669698C3018521938 @default.
• W2013669698 hasConceptScore W2013669698C530470458 @default.
• W2013669698 hasConceptScore W2013669698C71924100 @default.
• W2013669698 hasIssue "12" @default.
• W2013669698 hasLocation W20136696981 @default.
• W2013669698 hasLocation W20136696982 @default.
• W2013669698 hasOpenAccess W2013669698 @default.
• W2013669698 hasPrimaryLocation W20136696981 @default.
• W2013669698 hasRelatedWork W1967894062 @default.
• W2013669698 hasRelatedWork W2030434439 @default.
• W2013669698 hasRelatedWork W2037508728 @default.
• W2013669698 hasRelatedWork W2044570745 @default.
• W2013669698 hasRelatedWork W2050439103 @default.
• W2013669698 hasRelatedWork W2092771806 @default.
• W2013669698 hasRelatedWork W2113769490 @default.
• W2013669698 hasRelatedWork W2218005127 @default.
• W2013669698 hasRelatedWork W2241466075 @default.
• W2013669698 hasRelatedWork W2969515167 @default.

• next